A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 (NCT05557045)
Phase 1, FIH, Open-label, Nonrandomized, Multicenter Study of JZP815 in Participants With Advanced or Metastatic Solid Tumors Harboring Alterations in the MAPK Pathway
🩺 Plain-English Summary (8th-Grade Level)
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Who can join: Review the eligibility criteria below.
Location: Valkyrie Clinical Trials — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Valkyrie Clinical Trials — Los Angeles, California
- SCRI HealthOne — Denver, Colorado
- Florida Cancer Specialists - Lake Nona — Orlando, Florida
- Florida Cancer Specialists - Sarasota — Sarasota, Florida
- University of Chicago — Chicago, Illinois
- NYU Langone Health — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Oklahoma University — Oklahoma City, Oklahoma
- University of Pennsylvania — Philadelphia, Pennsylvania
- Sidney Kimmel Cancer Center — Philadelphia, Pennsylvania
- Tennessee Oncology - Nashville — Nashville, Tennessee
- Texas Oncology- Central South — Austin, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Texas Oncology- Gulf Coast — The Woodlands, Texas
- Virginica Cancer Specialists — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (215) 832-3750
Email: ClinicalTrialDisclosure@JazzPharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Cancer
- Intrapleural Catheter Daily Versus Three Times a Week Drainage — Houston, Texas
- Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer — Toronto, Ontario
- Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer — New York, New York
- FS120 Phase 1/1b Study in Patients With Advanced Malignancies — New Haven, Connecticut
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer — Encinitas, California
- Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) — Santa Rosa, California
Explore by condition: All Advanced Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.